Karrine Brade, PharmD

Come work as an ID pharmacist at @ucsfhealth.bsky.social! See the craziest cases, collaborate with the coolest pharmacists and physicians, teach trainees from pharmacy students to ID fellows!

sjobs.brassring.com/TGnewUI/Sear...

You've Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists This multicenter study highlights the critical role of ID pharmacists in supporting ID consult services, with 89% of 1,518 curbside inquiries from ID clinicians resulting in clinical management changes as recommended by the pharmacist. These findings emphasize the necessity of ID pharmacists in optimizing multidisciplinary patient care.

You've Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists

✅ Just Accepted
#IDSky

(1/2) Last week, 33 ID professionals gathered in Arlington, VA for IDSA’s Community of Leaders, a training program designed to equip mid- and senior-level professionals with the tools, insights, and network to drive career growth and lead meaningful change.

Our Division hosted the inaugural 2025 Colorado Infectious Diseases Symposium on April 19. The event was a tremendous success, uniting experts from across the state to advance learning, enhance collegiality, and improve health outcomes for patients in Colorado! A proud moment for #ColoradoID!

Antimicrobial Stewardship Pharmacist Job Description Summary The Clinical Pharmacy Specialist, Infectious Diseases/Antimicrobial Stewardship will participate in systemwide stewardship responsibilities, including MUSC facilities and MUSC ...

We’re expanding our stewardship program - help pioneer our contractual ASP initiative! This position will participate in our systemwide ASP program by establishing stewardship practices at MUSC Health affiliate sites! DM with any questions!

musc.wd1.myworkdayjobs.com/MUSC/job/SCM...

Three new UTI antibiotics active vs. ESBL organisms have been approved by the FDA in the past year alone! Which will make it to market first: pivmecillinam, sulopenem-probenecid, or gepotidacin? #IDsky

104. IDSA Difficult To Treat Gram negatives Guidance 2024 with Breakpoints podcast Podcast Episode · ID:IOTS - Infectious Disease Insight Of Two Specialists · 24/03/2025 · 1h 19m

IT’S A BREAKPOINTS BREAKOUT!!!

This week @erinmccreary.bsky.social & @juliejusto.bsky.social from @sidpharm.bsky.social #Breakpoints podcast join Callum & Jame to show ‘em how it’s done and discuss the IDSA Difficult-to-Treat Gram Negative guidance!!

podcasts.apple.com/gb/podcast/i...

#IDSky

IDSA is proud to celebrate the 33 extraordinary individuals accepted into the Leadership Institute’s 2025 Community of Leaders program. Congratulations to each member of the new class on their dedication to leadership development and community building in the field of ID/HIV! #FutureofID

Congratulations, @nicobarrosid.bsky.social, @bradeka.bsky.social, @janadickter.bsky.social, @jdfoxmd.bsky.social, @davidcgaston.bsky.social, @joelkammeyer.bsky.social, @mirellasalvatore.bsky.social, @suchindran.bsky.social, @boghuma.bsky.social, @anapaulavelez.bsky.social and @se-tid.bsky.social! 🎉

Real-World Applications of Imipenem/Cilastatin/Relebactam: Insights from a Multicenter Observational Cohort Study Multidrug-resistant (MDR) Gram-negative infections are a substantial threat to patients and public health. Imipenem/cilastatin/relebactam (IMI/REL) is a beta-lactam/beta-lactamase inhibitor with expanded activity against MDR Pseudomonas aeruginosa and carbapenem-resistant Enterobacterales. This study aims to describe the patient characteristics, prescribing patterns, and clinical outcomes associated with IMI/REL.

Real-World Applications of Imipenem/Cilastatin/Relebactam: Insights from a Multicenter Observational Cohort Study

✅ Just Accepted
#IDSky

"Disruptions in the workforce, even brief, can have far reaching consequences,” says IDSA member Joshua Barocas, MD.

Our press briefing explores the impact of disruptions in public health information: https://buff.ly/4k1NCg5

Study Finds 25% of Youth Experienced Homelessness in Denver in 2021, Significantly Higher Than Known Counts Study Finds 25% of Youth Experienced Homelessness in Denver in 2021, Significantly Higher Than Known Counts

A groundbreaking study led by @jabarocas.bsky.social and published in the American Academy of Pediatrics revealed that 25% of youth experienced homelessness in Denver in 2021—a troubling trend that's been rising since 2017. https://buff.ly/4h4Lbaw

ONE ANTIBIOTIC PK TABLE TO RULE THEM ALL

Absorption takes drug into blood from GI,
Vd spreads drug out to where bug calls home.
And after bacteria are doomed to die,
The drug’s eliminated on the porcelain throne

In the Land of Notion where this table doth lie…

#idSky #microsky #pharmsky #medsky

How do you spend your snowy Saturday? #snowday #denversnow #boardgames

PJIs & biofilm’s still keeping you up at night? Dr. Julie Ann Justo is joined by Dr’s Nicolas Cortes-Penfield, Jessica Seidelman, & Kerry LaPlante to discuss using abx to help treat these infections in the latest breakpoint episode # 110 “A Bone to Pick: Biofilm Busters for PJIs”. Listen today!

We are living in perilous times. Our research lab @cudeptofmedicine.bsky.social is hiring. Looking for someone who wants to make a positive impact in the lives of ppl who are marginalized! Spread the word!

cu.taleo.net/careersectio...

Summary of new antibiotic agents for the treatment of MDR Gram negative bacterial infections

doi.org/10.1016/S014...

#IDSky